BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
BioXcel Therapeutics has enrolled the first patients in a U.S. Department of War-funded Phase 2a clinical trial investigating its investigational drug BXCL501 (sublingual dexmedetomidine) for the treatment of acute stress reactions (ASR). The study, led by University of North Carolina at Chapel Hill's Institute for Trauma Recovery, aims to evaluate…